JLE

Hépato-Gastro & Oncologie Digestive

MENU

Association de biothérapies au cours des maladies inflammatoires chroniques intestinales : quel intérêt en pratique ? Volume 25, numéro 10, Décembre 2018

  • [1] Peyrin-Biroulet L., Sandborn W., Sands B.E. Selecting Therapeutic Targets in Inflammatory Bowel Diseases (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015;110:1324-1338.
  • [2] Peyrin-Biroulet L., Lemann M. Review article: Remission rates achievable by current therapies for inflammtory bowel disease. Aliment Pharmacol Ther. 2011;33:870-879.
  • [3] Hindryckx P., Vande Casteele N., Novak G. The expanding armamentarium for inflammatory bowel disease: How to choose the right drug[s] for our patients ? J Crohns Colitis. 2018;12:105-119.
  • [4] Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm Bowel Dis 2007 ; 13 : 2-11.
  • [5] Freiling E., Baumann C., Cuny J.F. Cumulative incidence of, risk factors for, and outcome of dematological complications of anti-TNF therapy in inflammatory bowel disease: A 14-year experience. Am J Gastroenterol. 2015;110:1186-1196.
  • [6] Yzet C, Dupas JL, Fumery M. Ustekinumab and anti-TNF combination therapy in patients with inflammatory bowel disease. Am J Gastrenterol 2016 ; 111 : 748-749.
  • [7] Leonardi C.L., Kimball A.B., Papp K.A. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-1674.
  • [8] Tillack C., Ehmann L.M., Friedrich M. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22 expressing Th 17 cells and respond to an anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567-577.
  • [9] Hirten R, Longman RS, Bosworth BP, et al. Vedolizumab and infliximab combination therapy in the treatment of Crohn's disease. Am J Gastroenterol 2015 ; 110 : 1737-1738.
  • [10] Wyant T., Fedyk E., Abhyankar B. An overview of the mechanism of action of the monoclonal antibody vedolizumab. J Crohns Colitis. 2016;10:1437-1444.
  • [11] Ben Horin S, Ungar B, Kopylov U et al. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor. Aliment Pharmacol Ther 2018 ; 47 : 1117-1125.
  • [12] Liu EY, Loomes DE. Ustekinumab and vedolizumab dual biologic therapy in the treatment of crohn's disease. Case Rep Med 2017 :5264216.
  • [13] Sheehy C., Murphy E., Barry M. Effective co-administration of infliximab and etanercept following the fialure of sequential anti-TNF agents in a patient with HLA-b27 associated arthropathy. Rheumatology. 2006;45:1314-1315.
  • [14] Genovese M.C., Cohen S., Moreland L. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004;50:1412-1419.
  • [15] Weinblatt M., Schiff M., Goldman A. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: A randomised clinical trial. Ann Rheum Dis. 2007;66:228-234.
  • [16] Greewald M.W., Shergy W.J., Kaine J.L. Evaluation of the safety of rutuximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis. Arthritis Rheumatol. 2011;63:622-632.
  • [17] Emery P., Deodhar A., Rigby W.F. Efficacy and safety of different doses and retreatment of rituximab : a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficay in MTX iNadequate rEsponders [SERENE]). Ann Rheum Dis. 2010;69:1629-1635.
  • [18] Genovese M.C., Breedveld F.C., Emery P. Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis. 2009;698:1894-1897.
  • [19] Cuchacovitch R., Garcia-Valladares I., Espinoza L.R. Combination biologic treatment of refractory psoriasis and psoriatic arthritis. J Rheumatol. 2012;39:187-193.
  • [20] Babalola O., Lakdawala N., Strober B.E. Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis : a case report. JAAD Case Report. 2015;1:3-4.
  • [21] Heinecke G.M., Luber A.J., Levitt J.O. Combination use of ustekinumab with other systemic therapies: A retrospective suty in a tertiary referral center. J Drugs Dermatol. 2013;12:1098-1102.
  • [22] Adisen E., Karaca F., Gurer M.A. When there is no single best biological agent : psoriasis and psoriatic arthritis in the samepatient responding to two different biological agents. Clin Exp Dermatol. 2008;33:164-166.
  • [23] Kitamura G., Mehr N., Anderson N. A case of tuberculosis in a patient on efalizumab and etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis. Dermatol Online J. 2009;15:11.
  • [24] Krell J.M. Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept. J Am Acad Dermatol. 2006;54:1099-1101.
  • [25] Gniadecki R., Bang B., Sand C. Combination of antitumour necrosis factor-alpha and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: A long-term case-series observational study. Br J Dermatol. 2016;174:1145-1146.
  • [26] Hamilton T.K. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy. J Drugs Dermatol. 2008;7:1089-1093.
  • [27] Gniadecki R., Bang B., Sand C. Combination of antitumour necrosis factor-alpha and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: A long-term case-series observational study. Br J Dermatol. 2016;174:1145-1146.
  • [28] Brakenhoff L.K., van der Heijde D.M., Hommes D.W. IBD and arthropathies: A practical approach to this diagnosis and management. Gut. 2001;60:1426-1435.
  • [29] Gisbert J.P., Marin A.C., McNicholl A.G. Systematic review with meta-analysis: The efficacy of a second anti-TNF in patients with inflammatory bowel diseases whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41:613-623.
  • [30] Rubin D., Feagan B., Driden G. The effect of vedolizumab on extraintestinal manifestations in patients with Crohn's disease in GEMINI 2. Inflamm Bowel Dis. 2016;22:105.
  • [31] Bethge J, Meffert S, Ellrichmann M, et al. Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis. BMJ Open Gastro 2017 ; 4 : e000127.
  • [32] Bonovas S., Fiorino G., Allocca M. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: A systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385-1397.
  • [33] Spiess C., Zhai Q., Carter P.J. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67:28-45.
  • [34] Baker K.F., Isaacs J.D. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis ? Ann Rheum Dis. 2018;77:175-187.
  • [35] Fleischmann R.M, Wagner F., Kivitz A. J. Safety, tolerability, and pharmacodynamics of ABT-122, a tumor necrosis factor – and interleukin-17 – targeted dual variable domain immunoglobulin, in patients with rheumatoid arthritis. Arthritis Rheumatol. 2017;76:2283-2291.
  • [36] Mease PJ, Genovese MC, Weinblatt M, et al. Phase 2 Study of ABT-122, a TNF- and IL-17A-Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis With Inadequate Methotrexate Response. Arthritis Rheumatol. 2018 May 31. doi : 10.1002/art.40579.[Epub ahead of print].